Amgen (AMGN) Expected to Announce Quarterly Earnings on Tuesday

Amgen (NASDAQ:AMGN) will likely be announcing its Q2 2026 results after the market closes on Tuesday, August 4th. Analysts expect Amgen to post earnings of $5.61 per share and revenue of $9.4337 billion for the quarter. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Interested persons are encouraged to explore the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 4:30 PM ET.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, topping the consensus estimate of $4.77 by $0.38. The firm had revenue of $8.62 billion for the quarter, compared to analyst estimates of $8.58 billion. Amgen had a net margin of 20.96% and a return on equity of 137.41%. Amgen’s quarterly revenue was up 5.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $4.90 earnings per share. On average, analysts expect Amgen to post $22 EPS for the current fiscal year and $24 EPS for the next fiscal year.

Amgen Trading Up 4.7%

Shares of NASDAQ AMGN opened at $393.97 on Tuesday. The company has a current ratio of 1.26, a quick ratio of 1.01 and a debt-to-equity ratio of 5.65. The company has a market cap of $212.63 billion, a price-to-earnings ratio of 27.22, a price-to-earnings-growth ratio of 3.80 and a beta of 0.41. Amgen has a 12-month low of $269.77 and a 12-month high of $391.29. The stock’s 50 day simple moving average is $352.31 and its 200 day simple moving average is $352.35.

Insider Transactions at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of Amgen stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $323.73, for a total value of $400,454.01. Following the transaction, the senior vice president directly owned 7,009 shares of the company’s stock, valued at $2,269,023.57. The trade was a 15.00% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 0.85% of the stock is owned by company insiders.

Institutional Investors Weigh In On Amgen

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Northern Trust Corp increased its position in Amgen by 0.6% during the fourth quarter. Northern Trust Corp now owns 6,181,658 shares of the medical research company’s stock worth $2,023,318,000 after acquiring an additional 37,178 shares during the period. Amundi grew its position in Amgen by 41.1% in the 4th quarter. Amundi now owns 3,396,945 shares of the medical research company’s stock worth $1,111,854,000 after purchasing an additional 988,856 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Amgen by 1.6% during the 4th quarter. Dimensional Fund Advisors LP now owns 3,230,979 shares of the medical research company’s stock worth $1,057,561,000 after purchasing an additional 52,389 shares during the period. Ameriprise Financial Inc. increased its holdings in shares of Amgen by 16.3% during the 2nd quarter. Ameriprise Financial Inc. now owns 2,467,959 shares of the medical research company’s stock worth $688,649,000 after purchasing an additional 345,242 shares during the period. Finally, Raymond James Financial Inc. raised its position in shares of Amgen by 1.2% during the third quarter. Raymond James Financial Inc. now owns 1,746,516 shares of the medical research company’s stock valued at $492,864,000 after buying an additional 20,888 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Wall Street Analyst Weigh In

AMGN has been the topic of several research analyst reports. Daiwa Securities Group lowered their target price on shares of Amgen from $410.00 to $390.00 and set an “outperform” rating on the stock in a research note on Wednesday, May 13th. Argus cut their price objective on Amgen from $400.00 to $375.00 and set a “buy” rating for the company in a research report on Wednesday, May 20th. Piper Sandler reiterated an “overweight” rating on shares of Amgen in a report on Friday, June 12th. UBS Group upped their target price on Amgen from $400.00 to $420.00 and gave the stock a “buy” rating in a research report on Monday, July 13th. Finally, Weiss Ratings downgraded shares of Amgen from a “buy (b)” rating to a “buy (b-)” rating in a report on Wednesday, July 15th. Two analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, fifteen have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $356.62.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.